Mesenchymal stromal cells to treat cardiovascular disease: Strategies to improve survival and therapeutic results

Panminerva Medica

Volumn 52, Issue 1, 2010, Pages 27-40

  Noort, W A ^a,b   Feye, D ^a   Van Den Akker, F ^a   Stecher, K D ^a   Chamuleau, S A J ^a   Sluijter, J P G ^a,b   Doevendans, P A ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Cardiovascular diseases; Mesenchymal stem cells; Stem cell transplantation

Indexed keywords

CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL TRANSPLANTATION; CYTOLOGY; HUMAN; MESENCHYMAL STEM CELL; REGENERATIVE MEDICINE; REVIEW; STROMA CELL; SURVIVAL RATE;

CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; CELL TRANSPLANTATION; HUMANS; MESENCHYMAL STEM CELLS; REGENERATIVE MEDICINE; STROMAL CELLS; SURVIVAL RATE;

EID: 77954726628     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (127)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181.
2. Francis GS. Pathophysiology of chronic heart failure. Am J Med 2001:110 Suppl 7A:37S-46S.
3. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-262
4. Virag JI, Murry CE. Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am J Pathol 2003;163:2433-2440
5. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature 2008;451:919-928
6. Murry CE, Field LJ, Menasche P. Cell-based cardiac repair reflections at the 10-year point. Circulation 2005;112:3174-3183
7. Strauer BE, Kornowski R. Stem cell therapy in perspective. Circulation 2003;107:929-934
8. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007;448:318-324 (Pubitemid 47080337)
9. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9:702-712
10. Noort WA, Sluijter JP, Goumans MJ, Chamuleau SA, Doevendans PA. Stem cells from in- or outside of the heart: isolation, characterization, and potential for myocardial tissue regeneration. Pediatr Cardiol 2009;30:699-709.
11. Liu ZJ, Zhuge Y, Velazquez OC. Trafficking and differentiation of mesenchymal stem cells. J Cell Biochem 2009;106:984-991
12. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
13. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol 2005;23:845-856
14. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008;451:937-942
15. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 2005;115:572-583
16. Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspumer H, Trinquart L et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117:1189-1200
17. Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, Nadal-Ginard B et al. Chimerism of the transplanted heart. N Engl J Med 2002;346:5-15.
18. Torella D, Ellison GM, Karakikes I, Nadal-Ginard B. Resident cardiac stem cells. Cell Mol Life Sci 2007;64:661-673
19. Sanchez A, Garcia-Sancho J. Cardiac repair by stem cells. Cell Death Differ 2007;14:1258-1261
20. van Poll D, Parekkadan B, Borel Rinkes IHM, Tilles AW, Yarmush ML. Mesenchymal stem cell therapy for protection ana repair of injured vital organs. Cellular and Molecular Bidengineering 2008;1:42-50.
21. Xu W, Zhang X, Qian H, Zhu W, Sun X, Hu J etdl. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 2004;229:623-631 /
22. Schafer R, Northoff H. Cardioprotection ana cardiac regeneration by mesenchymal stem cells. Panminerva Med 2008;50:31-39
23. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vase Biol 2008;28:1584-1595
24. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-77
25. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction 1. Am J Cardiol 2004;94:92-95 (Pubitemid 38813459)
26. Chen S, Liu Z, Tian N, Zhang J, Yei F, Duan B et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006;18:552-556
27. Meissner A, Wemig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 2007;25:1177-1181
28. Smits AM, van Vliet P, Metz CH, Korfage T, Sluijter JP, Doevendans PA et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology. Nat Protoc 2009;4:232-243
29. Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008;26:2201-2210
30. Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF. The infarct-ed myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 1999;44:232-241
31. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Ore Res 2006;98:1414-1421
32. Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005,112,1128-35
33. Jiang CY, Gui C, He AN, Hu XY, Chen J, Jiang Y et al. Optimal time for mesenchymal stem cell transplantation in rats with myocardial infarction. J Zhejiang Univ Sci B 2008;9:630-637
34. Dai W, Hale SL, Kloner RA. Role of a paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regen Med 2007;2:63-68
35. Berry MF, Engler AJ, Woo YJ, Pirolli TJ, Bish LT, Jayasankar V et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance 1. Am J Physiol Heart Circ Physiol 2006;290:H2196-H2203.
36. Shabbir A, Zisa D, Suzuki G, Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 2009;296:H1888-H1897.
37. Halkos ME, Zhao ZQ, Kerendi F, Wang NP, Jiang R, Schmarkey LS et al. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Res Cardiol 2008;103:525-536
38. Tomita S, Mickle DA, Weisel RD, Jia ZQ, Tumiati LC, AllidinaY et al. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg 2002;123:1132-1140
39. Ohnishi S, Yanagawa B, Tanaka K, MiyaharaY, Obata H, Kataoka M et al. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol 2007;42:88-97.
40. Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 2007;1:129-137
41. Masri C, Chandrashekhar Y. Apoptosis: a potentially reversible, meta-stable state of the heart. Heart Fail Rev 2008;13:175-179
42. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365
43. Silva WA, Jr., Covas DT, Panepucci RA, Proto-Siqueira R, Siufi JL, Zanette DL et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells 2003;21:661-669
44. Wang PP, Wang JH, Yan ZP, Hu MY, Lau GK, Fan ST et al. Expression of hepatocyte-like phenotypes in bone marrow stromal cells after HGF induction. Biochem Biophys Res Commun 2004;320:712-716
45. Sadat S, Gehmert S, Song YH, Yen Y, Bai X, Gaiser S etal. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun 2007;363:674-679
46. Hu X, Wang J, Chen J, Luo R, He A, Xie X et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg 2007;31:438-443 (Pubitemid 46329387)
47. Block GJ, Ohkouchi S, Fung F, Frenkel J, Gregory C, Pochampally R et al. Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem Cells 2009;27:670-681
48. Sheikh-Hamad D, Bick R, Wu GY, Christensen BM, Razeghi P, Poindexter B et al. Stanniocalcin-1 is a naturally occurring L-chan-nel inhibitor in cardiomyocytes: relevance to human heart failure. Am J Physiol Heart Circ Physiol 2003;285:H442-H448.
49. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-1586
50. Newman RE, Yoo D, LeRoux MA, nilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009;8:110-123
51. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007;104:11002-11007
52. Weber KT, Sun Y, Diez J. Fibrosis: a living tissue and the infarcted heart. J Am Coll Cardiol 2008;52:2029-2031
53. Li L, Zhang S, Zhang Y, Yu B, Xu Y, Guan Z. Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure. Mol Biol Rep 2009;36:725-731
54. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003;100:8407-8411
55. Ohnishi S, Sumiyoshi H, Kitamura S, Nagaya N. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett 2007;581:3961-3966
56. Mias C, Lairez O, Trouche E, Roncalli J, Calise D, Seguelas MH et al. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 2009;27:2734-2743
57. ManneUo F, Tonti GA, Bagnara GP, Papa S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 2006;24:475-481
58. Luttun A, Carmeliet P. De novo vasculogenesis in the heart. Cardiovasc Res 2003;58:378-389
59. Urbanek K, Cesselli D, Rota M, Nascimbene A, De Angelis A, Hosoda T et al. Stem cell niches in the adult mouse heart. Proc Natl Acad Sci U S A 2006;103:9226-9231
60. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004;22:377-384 (Pubitemid 38736621)
61. Mayer H, Bertram H, Lindenmaier W, Korff T, Weber H, Weich H. Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J Cell Biochem 2005;95:827-839
62. van PD, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008;47:1634-1643
63. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arte-riogenesis through paracrine mechanisms. Circ Res 2004;94:678-685
64. Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 2006;113:1451-1463
65. Robey TE, Saiget MK, Reinecke H, Murry CE. Systems approaches to preventing transplanted cell death in cardiac repair. J Mol Cell Cardiol 2008;45:567-581
66. Meluzin J, Mayer J, Groch L, Janousek S, Hornacek I, Hlinomaz O et al. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function. Am Heart J 2006;152:975-1015
67. Yoon YS, Park JS, Tkebuchava T, Luedeman C, Losordo DW. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation 2004;109:3154-3157
68. Rangappa S, Fen C, Lee EH, Bongso A, Sim EK. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann Thorac Surg 2003;75:775-779
69. Fukuda K. Reprogramming of bone marrow mesenchymal stem cells into cardiomyocytes. C R Biol 2002;325:1027-1038
70. Wang TZ, Ma AQ, Xu ZY, Jiang WH, Du Y [Differentiation of mesenchymal stem cells into cardiomyocytes induced by cardiomyocytes]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2005;30:270-275
71. Liu Y, Song J, Liu W, Wan Y, Chen X, Hu C. Growth and differentiation of rat bone marrow stromal cells: does 5-azacytidine trigger their cardiomyogenic differentiation? Cardiovasc Res 2003;58:460-468
72. Shim WS, Jiang S, Wong P, Tan J, Chua YL, Tan YS etal. Ex vivo differentiation of human adult bone marrow stem cells into cardiomy-ocyte-like cells. Biochem Biophys Res Commun 2004;324:481-488
73. Antonitsis P, Ioannidou-Papagiannaki E, Kaidoglou A, Charokopos N, Kalogeridls A, Kouzi-Koliakou K et al. Cardiomyogenic potential of human adult bone marrow mesenchymal stem cells in vitro. Thorac Cardiovasc Surg 2008;56:77-82.
74. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad SciUSA2005;102:l 1474-1479
75. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005; 111:150-156
76. Zhang D, Fan GC, Zhou X, Zhao T, Pasha Z, Xu M et al. Over-expression of CXCR4 on mesenchymal stem cells augments myoan-giogenesis in the infarcted myocardium. J Mol Cell Cardiol 2008;44:281-292
77. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 2008;77:134-142
78. Valiunas V, Doronin S, Valiuniene L, Potapova I, Zuckerman J, Walcott B et al. Human mesenchymal stem cells make cardiac connexins and form functional gap junctions. J Physiol 2004;555:617-626
79. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via tri-lineage differentiating capacity. Proc Natl Acad Sci USA 2009;106:14022-14027
80. Toma C, Pittenger MF, Cahill KS, Byrne B J, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-98
81. Martens TP, See F, Schuster MD, Sondermeijer HP, Hefti MM, Zannettino A et al. Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nat Clin Pract Cardiovasc Med 2006;3 Suppl 1:S18-S22.
82. Bartunek J, Wijns W, Heyndrickx GR, Vanderheyden M. Timing of intracoronary bone-marrow-derived stem cell transplantation after ST-elevation myocardial infarction. Nat Clin Pract Cardiovasc Med 2006;3 Suppl 1:S52-S56.
83. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vase Biol 2008;28:208-216
84. van RJ, Bax JJ, Beeres SL, bbets-Schneider P, Roes SD, Stokkel MP et al Intramyocardial bone marrow cell injection for chronic myocardial ischemia: A randomized controlled trial. JAMA 2009;301:1997-2004.
85. Muller-Ehmsen J, Whittaker P, Kloner RA, Dow JS, Sakoda T, Long TI et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol 2002;34:107-116
86. Terrovitis J, Lautamaki R, Bonios M, Fox J, Engles JM, Yu J et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol 2009;54:1619-1626
87. Christman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol 2006;48:907-913
88. Kofidis T, Lebl DR, Martinez EC, Hoyt G, Tanaka M, Robbins RC. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation 2005;112:1173-1177.
89. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol CeU Cardiol 2001;33:907-921
90. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006;27:1114-1122
91. Sacco A, Doyonnas R, Kraft P, Vitorovic S, Blau HM. Self-renewal and expansion of single transplanted muscle stem cells. Nature 2008;456:502-506
92. Torella D, Indolfi C, Goldspink DF, Ellison GM. Cardiac stem cell-based myocardial regeneration: towards a translational approach. Cardiovasc Hematol Agents Med Chem 2008;6:53-59
93. Haider HK, Ashraf M. Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol CeU Cardiol 2008;45:554-566
94. Datta SR, Brunei A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927
95. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25:1015-1024
96. Rosova I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008;26:2173-2182
97. Das R, Jahr H, van Osch G, Farrell E. The role of hypoxia in MSCs: Considerations for regenerative medicine approaches. Tissue Eng Part B Rev 2009.
98. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME et al. Progenitor cell trafficking is regulated by hypoxic gradients through HJP-1 induction of SDF-1. Nat Med 2004;10:858-864
99. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, et al. CXCR4-SDF-1 signalling, locomotion, chemo-taxis and adhesion. J Mol Histol 2004;35:233-245
100. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, SunT etal. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009;104:1209-1216
101. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006;24:1254-1264
102. Lord-Dufour S, Copland IB, Levros LC, Jr., Post M, Das A, Khosla C et al. Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1 alpha: Targeting G6PT with mum-baistatin analogs in hypoxic mesenchymal stromal cells. Stem Cells 2009;27:489-497
103. Suzuki K, Smolenski RT, Jayakumar J, Murtuza B, Brand NJ, Yacoub MH. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation 2000;102:HI216-III221.
104. Laflamme MA, Gold J, Xu C, Hassanipour M, Rosier E, Police S et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol 2005;167:663-671
105. Cho JA, Park H, Kim HK, Lira EH, Seo SW, Choi JS et al. Hypertheimia-treated mesenchymal stem cells exert antitumor effects on human carcinoma cell line. Cancer 2009; 115:311-323
106. Park H, Cho JA, Kim SK, Kim JH, Lee SH. Hyperthermia on mesenchymal stem cells (MSCs) can sensitize tumor cells to undergo cell death. Int J Hyperthermia 2008;24:638-648
107. Sreedhar AS, Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 2004; 101:227-257
108. Mearow KM, Dodge ME, Rahimtula M, Yegappan C. Stress-mediated signaling in PC 12 cells - the role of the small heat shock protein, Hsp27, and Akt in protecting cells from heat stress and nerve growth factor withdrawal. J Neurochem 2002;83:452-462
109. Gnecchi M, He H, Melo LG, Noiseaux N, Morello F, de Boer RA et al. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells 2009;27:971-979
110. Xu RX,Chen X,Hu SS,Chen JH,Liu XW,Liu XB et al. [Lovastatin protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis through activation ofPDK/Akt and ERK1/2 signaling pathways]. Zhonghua Xin Xue Guan Bing Za Zhi 2008;36:685-690
111. Zhang J, Cheng X, Liao YH, Lu B, YangY, LiBetaL Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovasc Drugs Ther 2005;19:13-21. (Pubitemid 40767768)
112. Yang YJ, Qian HY, Huang J, Li JJ, Gao RL, Dou KF et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vase Biol 2009;29:2076-2082
113. Zhang W, Su X, Gao Y, Sun B, Yu Y, Wang X et al Berberine protects mesenchymal stem cells against hypoxia-induced apoptosis in vitro. Biol Pharm Bull 2009;32:1335-1342
114. Wisel S, Khan M, Kuppusamy ML, Mohan IK, Chacko SM, Rivera BK et al. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (l-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 2009;329:543-550
115. Pons J, Huang Y, rakawa-Hoyt J, Washko D, Takagawa J, Ye J et al. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun 2008;376:419-422
116. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265-275
117. Herrmann JL, Wang Y, AbarbaneU AM, Weil BR, Tan J, Meldrum DR. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardiopro-tection. Shock 2010;33:24-30.
118. Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 2008;51:933-943
119. Li Y, Yu X, Lin S, Li X, Zhang S, Song YH. Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. Biochem Biophys Res Commun 2007;356:780-784
120. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypox-ia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005;46:1339-1350
121. Chang W, Song BW, Lim S, Song H, Shim CY, Cha MJ et al. Mesenchymal stem cells pretreated with delivered Hph-1-Hsp70 protein are protected from hypoxia-mediated cell death and rescue heart functions from myocardial injury. Stem Cells 2009;27:2283-2292
122. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-1201
123. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367-368
124. Mirotsou M, Zhang Z, Deb A, Zhang L, Gnecchi M, Noiseux N et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A 2007;104:1643-1648
125. Zhang Z, Deb A, Pachori A, He W, Guo J, Pratt R et al. Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. J Mol Cell Cardiol 2009;46:370-377
126. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008;16:571-579
127. Zhang M, Mai N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007;21:3197-3207 (Pubitemid 47565538)